Abstract The effect of b-blockers in ST-elevation myocardial infarction (STEMI) patients who have undergone primary percutaneous coronary intervention (PCI) has not been adequately evaluated. Using a large multi-center registry in Japan, we identified 3,692 patients who underwent PCI within 24 h from onset of STEMI and were discharged alive from 2005 to 2007. Three-year cardiovascular outcomes were compared between the 2 groups of patients with (N = 1,614) or without (N = 2,078) b-blocker prescription at discharge. Compared with patients in the no-b group, patients in the b group were younger, more frequently male, more often had hypertension and atrial fibrillation but less often had chronic obstructive pulmonary disease than in the no-b group. Statins and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers were more frequently prescribed in the b group. Crude incidence of cardiac death and/or recurrent myocardial infarction (cardiac death/MI) tended to be higher in the b group (7.6 vs. 6.2 %, log-rank p = 0.1). After adjusting for potential confounders, b-blockers were associated with significantly higher risk for cardiac death/MI (hazard ratio 1.43, 95 % CI: 1.06-1.94, p = 0.01). b-Blocker prescription at discharge was not associated with better cardiovascular outcomes in patients who underwent PCI after STEMI. Large-scale randomized controlled trials are needed to evaluate the role of b-blocker therapy in these patients.
Introduction
The current clinical guidelines for treatment of ST-segment elevation acute myocardial infarction (STEMI) recommend On behalf of the CREDO-Kyoto AMI registry investigators.
Electronic supplementary material The online version of this article (doi:10.1007/s12928-012-0137-9) contains supplementary material, which is available to authorized users. administration of oral b-blockers indefinitely to patients who have no contraindications [1, 2] . The guidelines were established on the basis of results from studies conducted in the pre-fibrinolytic era or from studies including a relatively small proportion of patients with early revascularization by thrombolytic therapy or percutaneous coronary intervention (PCI) [3, 4] . However, conclusions from observational studies in patients treated with PCI after STEMI were discordant regarding the efficacy of oral b-blocker therapy [5, 6] . In the Primary angioplasty in acute myocardial infarction (PAMI) study, it was reported that b-blockers after PCI were associated with lower 6-month mortality in patients with acute myocardial infarction (AMI) [5] . In contrast, in the j-Cypher study, b-blockers were not associated with 3-year mortality in patients who underwent PCI after STEMI and survived the index hospitalization [6] . However, the sample sizes were relatively small and neither the types nor the doses of b-blockers were known in the previous studies. Therefore, the present study was designed to examine whether prescription of b-blockers at discharge was independently associated with improved cardiovascular outcomes in patients who underwent PCI after STEMI using a recent large registry in Japan.
Methods
The Coronary REvascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) AMI registry is a physician-initiated non-company sponsored multi-center registry that enrolled consecutive AMI patients undergoing coronary revascularization within 7 days of the symptom onset between January 2005 and December 2007 across 26 tertiary hospitals in Japan (Supplemental Appendix A). Among 5,429 patients enrolled in the registry, 4,444 patients were diagnosed as STEMI. Excluding 494 patients who underwent PCI beyond 24 h and 258 patients who died during the index hospitalization, the current study population consisted of 3,692 patients who underwent PCI within 24 h from onset of STEMI and survived the index hospitalization (Fig. 1) . Demographics, clinical factors, angiographic data, and discharge medications were collected from hospital charts or hospital databases according to pre-specified definitions by experienced clinical research coordinators (Supplemental Appendix B). Follow-up data were obtained from hospital charts or by contacting patients or referring physicians through 3 years. The relevant review boards or ethics committees in all 26 participating centers approved the study protocol.
Definitions
Prior myocardial infarction (MI), heart failure (HF), hypertension, current smoking, atrial fibrillation, chronic obstructive lung disease (COPD), liver cirrhosis, and malignancy were regarded as present when these diagnoses were recorded in the hospital charts. Prior stroke was CABG coronary artery bypass surgery, PCI percutaneous coronary intervention, and STEMI ST-segment elevation myocardial infarction defined as infarction or intracranial bleeding with neurological symptoms lasting [24 h. Peripheral vascular disease was regarded to be present when carotid, aortic, or other peripheral vascular diseases were being treated or scheduled for surgical or endovascular interventions. Left ventricular ejection fraction (LVEF) was measured either by contrast left ventriculography or by echocardiography within 3 months after PCI and low LVEF was defined as LVEF B40 %.
During the follow-up, death was regarded as cardiac in origin unless obvious non-cardiac causes could be identified. MI was defined according to the definition in the Arterial Revascularization Therapy Study [7] . Events such as cardiac death and MI were adjudicated by a clinical event committee. Hospitalization for HF was defined as hospitalization due to worsening HF requiring intravenous drug therapy. The primary outcome measure for the current analyses was a composite endpoint of cardiac death and recurrent MI (cardiac death/MI). The secondary outcome measures assessed included all-cause death, cardiac death, recurrent MI, and hospitalization for HF.
Statistical methods
Cumulative incidences of clinical event rates were estimated by the Kaplan-Meier method and differences were assessed with the log-rank test. We used multivariable Cox proportional-hazards model stratified by centers to estimate the hazard ratio (HR) of b-blocker therapy at discharge for primary and secondary outcome measures by incorporating b-blocker therapy together with clinically relevant riskadjusting variables. Adjusted HR and their 95 % confidence interval (CI) were calculated. We computed adjusted cumulative incidence curves of b group and no-b group using the multivariable Cox proportional-hazards model in conjunction with methods described by Ghali et al. [8, 9] . The associations between b-blocker therapy at discharge and cardiovascular outcomes in the subgroup of patients with preserved and low LVEF were analyzed in the same way. We also performed subgroup analyses of different types and doses of b-blockers among patients in the b group.
Because clinical factors related to treatment selection may be expected to confound the rate of cardiovascular outcomes, we performed a propensity score-matched analysis between the b and no-b groups as a sensitivity analysis. Logistic regression was used to calculate the propensity score of prescription of b-blockers using clinically relevant variables and center. Patients in the b group were randomly matched to patients in the no-b group using a greedy matching strategy [10] . Survival analysis comparing the cases and controls was conducted using the Kaplan-Meier method, and statistical comparisons were drawn using the log-rank test.
All analyses were conducted by physicians (B.B. and N.O.) and a statistician (T.M.) using JMP 8 and SAS 9.2 (SAS Institute Inc., Cary, NC, USA), and all the reported p values were two-sided. A p \ 0.05 was regarded as statistically significant.
Results
Among the total of 3,692 study patients, oral b-blockers were prescribed in 1,614 patients (b group, 43.7 %) at hospital discharge, while 2,078 patients were not (no-b group, 56.3 %) (Fig. 1 ). There were significant differences in baseline characteristics between the b and no-b groups (Table 1) . Patients in the b group were younger, more frequently male, and more often had hypertension, high body weight, high body mass index (BMI), anterior MI, atrial fibrillation, and target of proximal left anterior descending artery. COPD were less prevalent in the b group. Statins, angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin receptor blockers, and warfarin were more frequently prescribed in the b group (Table 1) .
Clinical outcomes
Median follow-up duration was 955 (IQR: 693-1,248) days. Clinical follow-up were completed in 93.6 % at 1 year, and 87.2 % at 2 years. Three-year incidence of cardiac death/MI was 6.6 % for the entire study population. Crude 3-year incidence of cardiac death/MI was not significantly different between patients in the b group and those in the no-b group (7.6 vs. 6.2 %, log-rank p = 0.11, Table 2 ; Fig. 2a ). However, after adjusting for 39 potential confounders listed in Table 1 , the risk for cardiac death/MI was significantly higher in the b group (adjusted HR 1.43, 95 % CI: 1.06-1.94, p = 0.01, Supplemental Table 1 and Fig. 2a ). The risk for hospitalization for HF was also significantly higher in the b group, however, the risk for allcause death was not different between the groups (Table 2) .
Subgroup analyses
In 2,944 patients with LVEF data, 2,494 patients (84.7 %) had preserved LVEF at baseline. The differences in baseline characteristics between the b and no-b groups in the preserved-and low-LVEF subgroups were similar to the differences in the entire study population (Supplemental Tables 2 and 3 ). After adjusting for confounding variables, b-Blockers in myocardial infarction 141 Table 4 ). Crude incidence of 3-year cardiac death/ MI was significantly lower in patients who received carvedilol C10 mg per day than in patients who received carvedilol \10 mg per day (4.7 vs. 8.9 %, log-rank p = 0.02, Supplemental Table 5 ). However, after adjusting for clinically relevant risk-adjusting variables, the risk for cardiac death/MI was not significantly different (adjusted HR 0.65, 95 % CI: 0.38-1.05, p = 0.08, Supplemental Table 5 ).
Sensitivity analyses
Propensity score of prescription of b-blockers was calculated using 24 clinically relevant variables (listed in Supplemental Table 6 ). In the propensity-score matched model, no significant differences in the baseline characteristics were found between the b and no-b groups, except that patients in the b group more frequently had prior HF and shock at presentation (Supplemental Table 6 ). There was no significant difference in the 3-year incidence of cardiac death/MI between the b and no-b groups in this Variables are mean ± SD, n (%), or median (IQR)
ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, COPD chronic obstructive pulmonary disease, DES drug-eluting stent, CTO chronic total occlusion, eGFR estimated glomerular filtration rate, H2-blocker histamine type2 receptor blocker, LAD left anterior descending coronary artery, LMCA left main coronary artery, LVEF left ventricular ejection fraction model (7.6 vs. 6.1 %, log-rank p = 0.2, Supplemental Table 7 ). However, more hospitalizations for HF were observed in the b-group (7.2 vs. 3.9 %, log-rank p \ 0.0001) (Supplemental Table 7 ).
Discussion
The major findings of this recent registry analyses were as follows: (1) the 3-year cardiovascular event rate of patients who underwent PCI after STEMI was relatively low; (2) b-blocker prescription at discharge was not associated with better cardiovascular outcomes in these patients. Despite the recommendations of the clinical guidelines, b-blocker use in STEMI has been less prevalent in the realworld clinical practice [11] . In the current study population, only 43.7 % of patients received oral b-blocker therapy at discharge. That was less than the frequencies of b-blocker prescription reported from the PAMI study conducted in the USA (68.0 %) [5] , but similar to the rate reported in the Heart Institute of Japan Acute Myocardial Infarction registry (HIJAMI) study (32.2 %) and the j-Cypher study (38.4 %) conducted in Japan [6, 12] .
The main mechanisms of the beneficial effects of b-blockers in patients with STEMI are considered to be the prevention of the cardiotoxic effects of catecholamines and the attenuation of the myocardial oxygen demand. b-blockers are also thought to be effective in reducing tachyarrhythmic events. Previous studies conducted in the pre-PCI era showed markedly lower mortality rate with b-blocker therapy in STEMI patients [3, 4] . However, in the present study, relatively low 3-year cardiovascular event rate was observed despite the low prescription rate of b-blockers at discharge. In addition to the preserved LVEF in most STEMI patients who have undergone emergent PCI, the high use of up-to-date medications such as ACE-I/ angiotensin receptor blockers and statins may result in the improved clinical outcomes of these patients. On the other hand, the adverse effects of b-blockers such as coronary spasm should be considered in these patients as they are disadvantageous. In the Japanese b-blocker and Calcium Antagonist Myocardial Infarction (JBCMI) study, the incidence of coronary spasm was significantly higher in patients with b-blocker therapy than those with calcium antagonist therapy (1.2 vs. 0.2 %, p = 0.02), but no significant difference was observed in cardiac mortality (1.7 vs. 1.1 %, p = 0.37) [13] . It's important to note that a majority of STEMI patients have hypertension (85.9 % of patients in the b group had hypertension in the present study) and the adverse effects of b-blockers have been a concern in patients with hypertension on the basis of recent clinical trials [14] [15] [16] . 
Study limitations
Our study has several important limitations. First, 90.2 % of the b-blockers prescribed were carvedilol in the present study. The impacts of different types of b-blockers on clinical outcomes were difficult to compare. However, carvedilol, a nonselective b-blocker with alpha 1-adrenergic receptor blocking and antioxidant effects, has been reported to have superior cardioprotective effects compared to other b-blockers on reducing the risk of events after AMI [17, 18] . Second, the relatively low dose of b-blockers prescribed could be one of the reasons why b-blockers were not associated with better clinical outcomes in this study. The median dose of carvedilol was 5 mg per day in this study, which was lower than the dose previously reported. In the Carvedilol Post-Infarct Survival Control in LV Dysfunction (CAPRI-CORN) trial, 12.5-50 mg per day of carvedilol reduced all-cause mortality, cardiovascular-cause mortality, and reinfarction when given to patients with recent AMI and LVEF B40 % [19] . Another study reported that carvedilol produced dose-related reductions in mortality and hospitalization rate in patients with HF [20] . In the current analysis, use of higher-dose carvedilol (C10 mg per day) was associated with a tendency of better clinical outcomes compared with use of lower-dose carvedilol (\10 mg per day) in a riskadjusted model (p = 0.08). However, the relatively low dose of b-blockers prescribed in the study patients was probably attributed to the physical and racial differences of the study patients. Japanese patients had lower body weight compared to the American patients. The median body weight of the Japanese STEMI patients observed in the b group in this study was 62 (IQR: 54-70) kg, which is obviously lower compared to the American STEMI patients at 80 (IQR: 70-91) kg [21] . In addition, Asian patients are predisposed to hypotension and bradycardia with high-dose b-blockers [22] . According to investigations conducted in Japan, the approved dose of carvedilol for the treatment of hypertension, coronary artery disease, and HF is 2.5-20 mg per day for Japanese patients [23] . Thus, the dose of b-blockers used in this study is thought to be reasonable for the study patients and it definitely reflected the real-world clinical practice in Japan. Third, we do not have information on which patients in the b group continued b-blockers during the years after discharge. Prescription of b-blockers at discharge might not be representative of long-term use of b-blockers after STEMI. However, previous studies reported that [80 % of patients continued to receive b-blockers 6 months after AMI [24] . In addition, patients not discharged on b-blockers are unlikely to be started on them as outpatients [25] . Forth, the current study did not have adequate power to assess outcomes in the subgroup with low LVEF. In this study, the use of b-blockers was not associated with better clinical outcomes in patients with low LVEF. The current result in the low-LVEF subgroup was inconsistent with the previous report from the j-Cypher registry that showed b-blockers after primary PCI were associated with reduced 3-year mortality in a subgroup of patients with low LVEF [6] . It was also inconsistent with the PAMI study in which b-blockers were associated with lower 6-month mortality in patients with LVEF B50 % [5] . Although all of these studies are observational and including relatively small number of patients with low LVEF, beneficial effect of b-blocker for STEMI patients with low LVEF has been reported in a largescale randomized controlled trial in which about a half of the patients underwent reperfusion therapy mainly by thrombolytic therapy [19] . Finally, selection bias for use of b-blockers is inevitable in this type of observational study. Although we included potential confounders in the multivariable Cox proportional-hazards models and we tried to minimize the difference of baseline characteristics between patients in the b and no-b groups with propensity matching in the sensitivity analyses, we could not exclude influences of unmeasured confounders on clinical outcomes. The effect of b-blockers in patients with STEMI after successful PCI should be evaluated by a randomized controlled study with a large sample size.
Conclusions
In this study, oral b-blocker prescription at discharge was not associated with better cardiovascular outcomes in patients who underwent PCI after STEMI. Most of these patients had preserved LVEF and fair prognosis without b-blocker use. Large-scale randomized controlled trials are needed to evaluate the role of b-blocker therapy in these patients.
